Literature DB >> 31165649

Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment.

Antonio Raffone1, Antonio Travaglino2, Gabriele Saccone1, Anna Di Maio3, Antonio Mollo1, Massimo Mascolo2, Rossella De Rosa1, Giuseppe De Placido1, Luigi Insabato2, Fulvio Zullo1.   

Abstract

Objective: The conservative treatment of endometrial hyperplasia without atypia (HWA), atypical endometrial hyperplasia (AH/EIN) and early endometrioid carcinoma (EEC) is based on progestins. We aimed to assess whether diabetes mellitus affects the responsiveness of HWA, AH/EIN and EEC to conservative treatment, through a systematic review and meta-analysis. Study design: Electronic databases were searched for studies assessing the outcome of conservative treatment in HWA, AH/EIN and EEC, stratified based on the diagnosis of diabetes mellitus. The association of diabetes mellitus with treatment failure was assessed by using odds ratio (OR). A p-value  < .05 was considered significant. The risk of publication bias was assessed by using a funnel plot. A subgroups analyses was performed based on histologic diagnosis of benignity (HWA) or premalignancy/malignancy (AH/EIN or EEC).
Results: Six studies with 876 patients (383 HWA, 365 AH/EIN and 128 EEC) were included. Overall, diabetes mellitus was not associated with outcome of treatment (OR = 1.20; p = .62). The association was not significant in both the HWA subgroup (OR = 0.95; p = .93) and in AH/EIN and EEC subgroup (OR = 1.43; p = .46). There was no significant risk of publication bias. Conclusions: Diabetes mellitus does not affect the outcome of conservative treatment in HWA, AH/EIN and EEC.

Entities:  

Keywords:  Endometrial hyperplasia; diabetes; endometrial intraepithelial neoplasia; endometrioid carcinoma; fertility-sparing

Mesh:

Year:  2019        PMID: 31165649     DOI: 10.1080/09513590.2019.1624716

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  7 in total

1.  ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2021-02       Impact factor: 4.064

2.  LncRNA SNHG16 induced by TFAP2A modulates glycolysis and proliferation of endometrial carcinoma through miR-490-3p/HK2 axis.

Authors:  Guangyu Zhang; Anjun Ma; Yuqin Jin; Guoyou Pan; Cong Wang
Journal:  Am J Transl Res       Date:  2019-11-15       Impact factor: 4.060

3.  Management of Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Patients After Primary Fertility-Sparing Therapy.

Authors:  Junyu Chen; Dongyan Cao; Jiaxin Yang; Mei Yu; Huimei Zhou; Ninghai Cheng; Jinhui Wang; Ying Zhang; Peng Peng; Keng Shen
Journal:  Front Oncol       Date:  2021-09-09       Impact factor: 6.244

4.  Effect and Management of Excess Weight in the Context of Fertility-Sparing Treatments in Patients With Atypical Endometrial Hyperplasia and Endometrial Cancer: Eight-Year Experience of 227 Cases.

Authors:  Ying Shan; Meng Qin; Jie Yin; Yan Cai; Yan Li; Yu Gu; Wei Wang; Yong-Xue Wang; Jia-Yu Chen; Ying Jin; Ling-Ya Pan
Journal:  Front Oncol       Date:  2021-11-05       Impact factor: 6.244

5.  MicroRNA-641 Inhibits Endometrial Cancer Progression via Targeting AP1G1.

Authors:  Yanfen Dong; He Yang; Handan Hua
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-30       Impact factor: 2.650

6.  Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups.

Authors:  Antonio Travaglino; Antonio Raffone; Cristina Stradella; Rosanna Esposito; Paola Moretta; Cinzia Gallo; Giuliana Orlandi; Luigi Insabato; Fulvio Zullo
Journal:  Arch Gynecol Obstet       Date:  2020-04-15       Impact factor: 2.344

7.  Significance of serum and pathological biomarkers in fertility-sparing treatment for endometrial cancer or atypical hyperplasia: a retrospective cohort study.

Authors:  Yiqin Wang; Rong Zhou; Xiaobo Zhang; Huixin Liu; Danhua Shen; Jianliu Wang
Journal:  BMC Womens Health       Date:  2021-06-23       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.